Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.

Bonafede, Machaon M K; McMorrow, Donna; Proudfoot, Clare; Shinde, Shraddha; Kuznik, Andreas; Chen, Chieh-I

Bonafede, Machaon M K; McMorrow, Donna; Proudfoot, Clare; Shinde, Shraddha; Kuznik, Andreas; Chen, Chieh-I.

Afiliação

Bonafede MMK; Senior Director of Outcomes Research, Truven Health Analytics, an IBM Company, Cambridge, MA.
McMorrow D; Lead Analyst, Truven Health Analytics, an IBM Company.
Proudfoot C; Evidence Lead, Sarilumab, Sanofi, Bridgewater, NJ.
Shinde S; Research Analyst, Health Economics and Outcomes Research, Sanofi.
Kuznik A; Senior Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Tarrytown, NY.
Chen CI; Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals.

Am Health Drug Benefits ; 11(4): 192-202, 2018 Jun.

Article em En | MEDLINE | ID: mdl-30464787

Palavras-chave

alternative mechanisms of action; cost; persistence; rheumatoid arthritis; switching treatment; synthetic DMARD; treatment cycling; treatment persistence; tumor necrosis factor inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Financiamentos_gastos Bases de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Am Health Drug Benefits Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Marrocos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google